Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients

NCT ID: NCT01755845

Last Updated: 2016-04-28

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2016-12-31

Brief Summary

The purpose of this study is to determine the efficacy and safety of consolidation chemotherapy with paclitaxel plus cisplatin (2 cycles per 3 weeks) following radical hysterectomy and adjuvant chemoradiation (2 cycles per 4 weeks) for high risk early stage cervical cancer.

Detailed Description

Cervical carcinoma is one of the most common gynecologic cancers worldwide. Early stage cervical cancer can be treated effectively with either radiotherapy or radical hysterectomy plus pelvic lymph node dissection. However, several pathological risk factors, such as lymph node metastasis, the involvement of vaginal resection margin, and the parametrial invasion, have been identified to compromise the patient prognosis.

Concurrent radiotherapy with cisplatin-based chemotherapy has become the standard treatment for patients with cervical cancer. However, many patients with pathological risk factors treated with concurrent radiotherapy plus single agent cisplatin still suffered from the local or distant relapse. How to improve the treatment outcome of these patients is a very important issue and requires further clinical investigation.

Paclitaxel has been demonstrated to be a good radiosensitizer. In addition, paclitaxel/cisplatin combination chemotherapy was demonstrated to have superior progression-free survival than platinum alone in some phase Ⅱ studies. In addition, it is not yet known whether chemotherapy and radiation therapy are more effective when given with consolidation chemotherapy in treating cervical cancer.

Therefore, the investigators are going to perform the efficacy and safety study of postoperative concurrent paclitaxel/cisplatin chemotherapy and radiotherapy with consolidation chemotherapy in high-risk patients with early-stage cervical cancer following radical hysterectomy.

Conditions

Cervical Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Arm 1

Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area. After completion of chemoradiotherapy, patients receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

paclitaxel

Intervention Type: DRUG

cisplatin

Intervention Type: DRUG

radiotherapy

Intervention Type: RADIATION

Arm 2

Patients receive chemoradiotherapy as in arm 1.

Group Type: ACTIVE_COMPARATOR

paclitaxel

Intervention Type: DRUG

cisplatin

Intervention Type: DRUG

radiotherapy

Intervention Type: RADIATION

Interventions

paclitaxel

Intervention Type: DRUG

cisplatin

Intervention Type: DRUG

radiotherapy

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• Undertaken radical hysterectomy with diagnosis of invasive cervical cancer I a2-II b (non-small cell type)
• One or more risk factors (lymph node involvement, resection margin involvement, parametrial involvement)
• Eastern Cooperative Oncology Group 0-2
• Expected life span over 6 months.
• No distant metastasis
• Adequate bone marrow functions (absolute neutrophil count≥ 1,500/ul, blood platelet≥ 100,000/ul, haemoglobin≥ 10g/dl)
• Adequate renal functions(serum creatinine ≤ 1.5mg/dl)
• Adequate liver functions (serum bilirubin ≤ 1.5mg/dl, aspartate aminotransferase/alanine aminotransferase ≤ 3 times(normal value)
• Written informed consent

Exclusion Criteria

• Previous history of chemotherapy or radiation
• Hypersensitive reaction to platinum/paclitaxel agent
• History of other cancer
• Concurrent systemic illness not appropriate for chemotherapy
• Active infection requiring antibiotics
• Pregnancy
• Metastasis to paraaortic lymph node

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

xie congying

OTHER

Sponsor Role: lead

Responsible Party

xie congying

Director

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

The First Affiliated Hospital of Wenzhou Medical College

Wenzhou, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

congying xie, MD

Role: CONTACT

wzxiecongying@163.com

+86-577-88069316

Facility Contacts

congying xie

Role: primary

wzxiecongying@163.com

+86-577-88069316

Other Identifiers

WZMC-11256

Identifier Type: -

Identifier Source: org_study_id